Breaking News Instant updates and real-time market news.

2019-03-05 16:22:52

HSDT

Helius Medical

$6.82

-0.15 (-2.15%)

16:22

03/05/19

03/05

16:22

03/05/19

16:22

Helius Medical initiated with an Outperform at Oppenheimer

Oppenheimer analyst Steven Lichtman started Helius Medical with an Outperform rating and $10 price target. While FDA approval of the company's Portable Neuromodulation Stimulator device is still pending and market development work remains, the "opportunity ahead is significant," Lichtman tells investors in a research note. He points out that 2.1M people in the U.S. suffer from chronic symptoms of traumatic brain injury with a primary complication of balance or gait disability. The analyst sees 2019 as a key year for Helius as it awaits FDA approval and begins a rollout in Canada.

14

Mar

HSDTHelius Medical

$6.82

-0.15 (-2.15%)

06/19/18

BTIG

06/19/18DOWNGRADEBTIGNeutral

Helius Medical downgraded to Neutral from Buy at BTIG

06/19/18

BTIG

06/19/18DOWNGRADEBTIGNeutral

Helius Medical downgraded to Neutral at BTIG on delay in PNS clearance

As reported, BTIG analyst Sean Lavin downgraded Helius Medical to Neutral from Buy citing yesterday's announced delay in filing for the FDA clearance of its Portable Neuromodulation Stimulator investigational medical device in Q3 rather than Q2. The analyst notes that the delay raises the risk of the company running out of cash before clearance and may force it to raise more capital, putting the spotlight on the management's credibility. Lavin adds that given the rise in the stock price to his prior target of $14, a Neutral rating is "more appropriate".

11/20/18

BTIG

11/20/18UPGRADEBTIGBuy

Helius Medical upgraded to Buy from Neutral at BTIG

11/20/18

BTIG

11/20/18UPGRADETarget $14BTIGBuy

Helius Medical upgraded to Buy from Neutral at BTIG

BTIG analyst Sean Lavin upgraded Helius Medical to Buy from Neutral with a price target of $14. The analyst notes that the company's recent $17.5M stock offering removing the overhang of capital need that was cited in his prior downgrade. Lavin adds that Helius Medical now has the funding to operate until at least the middle of 2019 and sees the stock price retreat from $13 in June to $8 as an opportune time to buy, particularly in light of the recent announcement of the Clinical Experience Programs being in the works at two prestigious U.S. neurorehab centers that validate PoNS therapy.